New Registry Opens for Patients Seeking Effective, Non-Toxic Treatment for Advanced Melanoma: Perseus PCI’s Promising VACCINE for Cancer Takes Next Step Toward FDA Trials
Grand Cayman, Cayman Islands (PRWEB) March 24, 2014 -- “The creation of the new Perseus Treatment Registry will provide an important platform for gathering data so that we might move closer to FDA compliance and trials,” explains Thomas Wagner, Ph.D., renowned biomedical scientist and creator of the vaccine. “In our own trials, we have found our vaccine to be very effective in treating Stage III and IV melanoma patients, and it is our goal to cut in half the current rate of cancer recurrence.”
Perseus professionals will select 20 patients, based on qualifying criteria, to receive the entire treatment for $10,000; standard costs for the protocol are $50,000. Those that qualify and are selected for the $40,000 subsidy will receive the full vaccine protocol and their data will be used to support the U.S. FDA trial process. Treatment includes travel and onsite care in the Cayman Islands. Basic requirements for eligibility include:
Patient must be 18 years or older
Diagnosis of melanoma cancer; patients with other solid tumor diseases may be eligible
Availability of one mg of patient’s tumor tissue
Patient’s immune system must be functional
Melanoma patients interested in enrolling for the Perseus vaccine are urged to call 866-299-0750 before April 30, 2014.
“This vaccine has given many cancer patients their life back and we want to make it more widely available to those seeking an effective, non-toxic therapy to treat advanced stages of melanoma,” continued Dr. Wagner. “By investing in patient subsidies now, we can accelerate the data collection required by the FDA, and move closer to fulfilling the promise of this immunotherapy vaccine.”
About the Perseus PCI Cancer Vaccine
The alternative cancer treatment was developed by Thomas Wagner, Ph.D., co-founder of Perseus PCI, and an innovator responsible for pioneering some of the past half-century’s most important biomedical technologies. The Perseus PCI vaccine arms the immune system to destroy the tumor with the patient’s own T-cells, and creates a lifetime immunity to the disease. Approved by the Health Practice Commission of the Cayman Islands for research, the vaccine has gone through Phases I and II clinical trials in the U.S. for treatment of advanced stage melanoma, renal cell carcinoma and neuroblastoma. Visit http://www.melanomaregistry.com/
Danny Katz, First Source Interactive, http://www.firstsourceinteractive.com, (800) 672-1285 Ext: 3, [email protected]
Share this article